Veeva Systems (VEEV)
NYSEHealth CareSoftware - ApplicationSnapshot 2026-09-04
$275.09-3.27%
Close 2026-09-04 · 1-day change
NYSEHealth CareSoftware - ApplicationSnapshot 2026-09-04
Intact: The reason to own it still holds.
Veeva grows revenue about 14% yearly, reaching $3.64 billion in 2027. Profit per share rises to $9.05, showing steady earnings growth. New products and acquisitions boost its market position. The stock trades below peers, offering value with strong fundamentals.
Competition could slow revenue growth and hurt margins. If new products fail to gain traction, earnings may fall short. Rising costs or market shifts could pressure profitability.
The market prices in about 14% revenue growth and values Veeva roughly 12% below our fair value near $219. Our fair value aligns closely with the Street median, reflecting justified expectations.
Breaks if: Competitive threats materially slow revenue growth or product adoption
Breaks if: Non-GAAP EPS falls below $8.5 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue growth and AI development. The current thesis state is stable, supported by recent earnings beats and a strong financial performance.
The market currently prices VEEV at a premium compared to its peers, reflecting justified expectations based on its recent performance. The expectations gap is narrow, indicating that the market anticipates continued solid results.
Management is on track to drive revenue growth and improve profitability, as evidenced by strong recent financial results. However, there is elevated risk due to potential economic headwinds that could impact performance.
The thesis hinges on VEEV's ability to maintain its growth trajectory and manage risks related to economic conditions. Key factors include guidance updates from management and performance of sector peers, which could influence market sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Strong revenue growth guidance for fiscal year 2027 reinforces this view. Advances in AI and agentic labor platform development also contribute to the improved read.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Veeva projects non-GAAP EPS of approximately $9.05 for fiscal year 2027.
Breaks if: Total revenue falls below $3.5 billion in FY27
Veeva continues to focus on quarterly revenue growth, achieving $835.95 million in 2026-Q4.
Over the next 1 to 3 years, VEEV's fundamentals appear strong, but external economic factors present risks. Not investment advice.